

THIS PRESS RELEASE IS RESTRICTED AND IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY AND WHETHER IN WHOLE OR IN PART, INTO OR IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, REPUBLIC OF SOUTH AFRICA, JAPAN OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL.

ADVERTISEMENT - This announcement is relating to the Company's (as defined below) launch of its Offering (as defined below) and the admission of the Offer Shares (as defined below) on Euronext Amsterdam and Euronext Brussels. This announcement does not constitute a prospectus. This announcement is for information purposes only and is not intended to constitute, and should not be construed as, an offer to sell or a solicitation of any offer to buy shares in any jurisdiction, including the United States, Canada, Australia, Japan, the Republic of South Africa and any jurisdiction where the Offer Shares cannot be lawfully made to existing shareholders (a "**Restricted Jurisdiction**"). The English version of the Prospectus (as defined below), which includes a Dutch summary, has been approved by the Dutch Authority for the Financial Markets (Stichting Autoriteit Financiële Markten) (the "**AFM**"), was published and made available at no cost at the start of the offer period through the corporate website of the Company <https://www.avantium.com/equityraise/>, subject to securities law restrictions in certain jurisdictions. An offer to acquire Offer Shares (as defined below) pursuant to the Offering will be made, and any potential investor should make their investment, solely on the basis of information that will be contained in the Prospectus and in particular the "Risk Factors" section. Potential investors should read the Prospectus (and notably the risk factors section) before making an investment decision in order to fully understand the potential risks and rewards associated with the decision to invest in the Offer Shares. The approval of the Prospectus by the AFM should not be understood as an endorsement of the quality of the Offer Shares and the Company.

Avantium announces the launch of a public offering of up to €45 million to accelerate the global transition to renewable and circular plastics

Capital raise supported by long-term shareholders

AMSTERDAM, 6 April 2022, 08:15 hrs CET - Avantium N.V. (the "Company" or "Avantium"), today announces the launch of a capital increase by means of a public offering with a priority allocation period for its existing shareholders, a retail offering and a private placement (the "Offering"), for an amount of up to €45 million.

Key terms of the Offering

- Offering comprising a priority entitlement for existing institutional and retail shareholders that will be open only to eligible existing shareholders (as described below in *Terms of the Offering*) (the "**Priority Allocation Offering**"), as well as a public offering in the Netherlands to retail investors (the "**Retail Offering**") and a private placement to qualified institutional investors (the "**Private Placement**").
- Certain existing long-term shareholders of Avantium, including funds managed by APG Asset Management N.V., investors represented by Wierda en Partners Vermogensbeheer B.V., Navitas B.V., Robeco Institutional Asset Management B.V. and other shareholders have irrevocably undertaken to subscribe for an aggregate amount of €12.2 million, or 27% of the Offering.
- Net proceeds will be used to (i) further develop plantMEG™ technology and to scale-up towards further commercialisation via technology licensing, (ii) further develop biorefinery and CO₂ based chemicals and polymers technologies, as well as assess economic feasibility and scale-up towards further commercialisation and (iii) for general corporate purposes, working capital and overall funding.

- The maximum subscription price has been set at €4.60 per new share. The maximum subscription price is indicative. The final offer price and the number of Offer Shares offered in the Offering will be determined following the Offering period on the basis of a book-building process.

Indicative timetable

- The offering period for the Priority Allocation Offering and the Retail Offering will take place from 09:00 hrs Central European Time (CET) on 6 April 2022 until 17:30 hrs CET on 13 April 2022.
- The offering period for the Private Placement will take place from 09:00 hrs CET on 6 April 2022 until 17:30 hrs CET on 14 April 2022.
- The offering period is subject to acceleration or extension of the timetable for the Offering.

Tom van Aken, Chief Executive Officer of Avantium, comments: *"We have achieved several pivotal milestones over the last few months, with the final investment decision on the construction of our FDCA Flagship Plant, the closing of the related €192.5 million financing package, as well as bringing important new partners on board. With this capital raise, we look forward to advance our innovative plantMEG™ technology towards commercialisation and develop our biorefinery, CO₂ chemicals and polymer technologies. We thank our long-term shareholders for their continuous support and participation in this transaction. We welcome all shareholders and new investors to acquire shares in the Offering and join our mission to accelerate the transition from fossil-based to renewable and circular plastics."*

Reasons for the Offering and use of proceeds

The reason for the Offering is to enable the Company to cover its existing expenses and to establish a reserve for the future and ongoing expenses of the Company, including for investments in the commercialisation of Avantium's technology programmes, such as its portfolio of technologies beyond YXY® Technology, being the plantMEG™ technology and the biorefinery and CO₂ based chemicals and polymers technologies, and for general corporate purposes, working capital and overall funding, such as allowing sufficient funding in conjunction with the secured €90 million debt financing for the FDCA Flagship Plant and allowing positive cash balances for the following three years.

The Company currently anticipates to use the net proceeds of the Offering as follows:

- 60% of the net proceeds of the Offering to further develop plantMEG™ technology (Ray Technology™) and to scale-up towards further commercialisation via technology licensing;
- 10% of the net proceeds of the Offering to further develop biorefinery (Dawn Technology™) and CO₂ based chemicals and polymers technologies (Volta Technology) as well as to assess economic feasibility and scale-up towards further commercialisation; and
- 30% of the net proceeds of the Offering for general corporate purposes, working capital and overall funding.

Based on its requirements under Avantium's current business plan, the current cash resources together with the full net proceeds from the Offering should enable the Company to fund its working capital for the next 3 years and to reach its next significant operational and industrial milestones, including the commissioning of the FDCA Flagship Plant in 2024 and the final investment decision (expected in 2024) for the construction of the first commercial plant for the production of plantMEG™ and plantMPG™ using Ray Technology™, jointly with Cosun Beet Company.

Terms of the Offering

The Company's existing shareholders to whom the Company may lawfully offer the Offer Shares in the Offering, which will exclude any existing shareholder located in a Restricted Jurisdiction, (the "**Priority Shareholders**") will be granted a priority entitlement to subscribe for shares in the Offering (the "**Offer Shares**") pro-rata their shareholding in the Company as held on 5 April 2022.

The Offering consists of (i) a priority allocation offering of Offer Shares that will be open only to existing shareholders to whom and in such jurisdictions such offering may lawfully be made and who are not located in a Restricted Jurisdiction (the "**Priority Allocation Offering**"), (ii) a public offering in the Netherlands to retail investors, (the "**Retail Offering**"), and (iii) a private placement to qualified investors (within the meaning of Regulation (EU) 2017/1129 (the "**Prospectus Regulation**"), institutional investors outside the European Union (the "**EU**") and a limited number of other investors in member states of the EU in reliance on article 1(4)(b), article 1(4)(c) and/or article 1(4)(d) of the Prospectus Regulation (the "**Private Placement**").

Issue amount and number of new shares to be issued

The amount of the Offering is up to €45 million. The number of new shares to be issued will be determined based on the final offer price.

Subscription price

The maximum subscription price of the Offer Shares is €4.60 per new share. This maximum price does not predetermine under any circumstances the final subscription price that may be set.

The subscription price of the new shares offered under the Priority Allocation Offering and the Retail Offering will be equal to the subscription price of the new shares offered under the Private Placement. The final number of shares to be issued as well as the final price of the Offering will be determined following the end of the Private Placement, scheduled for 17:30 hrs CET on 14 April 2022, and will be the subject of a subsequent press release.

Subscription commitments

The Company has received unconditional and irrevocable commitments from funds managed by APG Asset Management N.V., investors represented by Wierda en Partners Vermogensbeheer B.V., Navitas B.V., Robeco Institutional Asset Management B.V. and other shareholders to participate in the Offering and subscribe for Offer Shares for an aggregate amount of €12.2 million, or 27% of the Offering.

Lock-up undertakings

The Company has agreed to a lock-up period expiring 180 calendar days following the date of settlement of the Offering, subject to certain customary exceptions.

The management board and supervisory board have agreed to a lock-up period expiring 180 calendar days following the date of settlement of the Offering, subject to certain customary exceptions.

The Joint Bookrunners (as defined below) may waive those lock-up restrictions under the Placement Agreement.

Subscription in the Offering

Detailed information about the Offering and a FAQ are available on Avantium's website <https://www.avantium.com/equityraise/>. An information line for retail investors is also available (please see details below).

Priority Allocation Offering

The capital increase will be carried out with a priority entitlement period for Priority Shareholders of 6 consecutive trading days from 09.00 hrs CET on 6 April 2022 until 17:30 hrs CET on 13 April 2022, granted to the shareholders registered as of 5 April 2022 (the "**Registration Date**"). Within the priority entitlement period, Priority Shareholders may subscribe in the Offering pro-rata their holding in the Company's share capital. Each Priority Shareholder will be granted one non-transferable entitlement per ordinary share it holds. Such entitlement will grant the Priority Shareholder a right to subscribe in the Priority Allocation Offering for Offer Shares pro rata to its shareholding in the Company.

Each entitlement allows a Priority Shareholder to subscribe with priority for up to €1.44. By way of an example: a Priority Shareholder who holds 150 ordinary shares at the Registration Date may apply for the priority allocation in respect of the Offer Shares for a total value of €216 (equal to 150 times €1.44). The number of Offer Shares to be allocated with priority to that Priority Shareholder can be calculated by dividing €216 by the final offer price per Offer Share in the Offering, which will be determined on or about 14 April 2022, following the close of the book-building process. For the avoidance of doubt, the €1.44 amount bears no relation to the final offer price to be determined following the book-building process.

Private Placement and Retail Offering

The new shares not subscribed for with priority entitlements will be subject to:

- a public offering in the Netherlands to retail investors, open from 09.00 hrs CET on 6 April 2022 until 17:30 hrs CET on 13 April 2022, and
- a private placement to institutional investors, open from 09.00 hrs CET on 6 April 2022 until 17:30 hrs CET on 14 April 2022 .

Priority Shareholders who wish to subscribe for more than their pro-rata shareholding, i.e. the number of entitlements held times €1.44, must place an order in the context of the Retail Offering or the Private Placement, it being specified that the Priority Shareholders do not benefit from any further priority in such case.

Advisors

ABN AMRO Bank N.V. (in collaboration with ODDO BHF SCA), Joh. Berenberg, Gossler & Co. KG, and Bryan, Garnier & Co Limited (with investment services pursuant to the EU Markets in Financial Instruments Directive (2014/65/EU) to be rendered by Bryan Garnier Securities SAS) are acting as global coordinators (the "**Joint Global Coordinators**") and, together with Bank Degroof Petercam SA/NV, as joint bookrunners for the Offering (the "**Joint Bookrunners**"). Oaklins is financial advisor to Avantium.

Placement

The Offering will be subject to a placement agreement between the Company and the Joint Bookrunners (the "**Placement Agreement**") which may be terminated by the Joint Global Coordinators (acting jointly on behalf of the Joint Bookrunners) at any time on or prior to the settlement date, subject to certain customary conditions for this type of agreement.

Indicative timetable

6 April 2022	Launch of the Priority Allocation Offering, the Retail Offering and the Private Placement at 9:00 hrs CET
13 April 2022	Closing of the Priority Allocation Offering and the Retail Offering at 17.30 hrs CET
14 April 2022	Closing of the Private Placement at 17:30 hrs CET Determination of the final terms of the capital increase (final offer price and number of new shares to be issued) Execution of the Placement Agreement
15 April 2022	Company's press release announcing the results of the Offering Euronext notice on the results of the Offering

19 April 2022	Admission to trading of the new shares on Euronext Amsterdam and Euronext Brussels at 09.00 hrs CET
21 April 2022	Settlement and delivery of the new shares at 09.00 hrs CET

The Priority Allocation Offering period, the Retail Offering period and the Private Placement period are subject to acceleration or extension of the timetable for the Offering.

Availability of the Prospectus

The Offering is being made only by means of a prospectus (the "**Prospectus**"), approved by, and filed with, the Dutch Authority for the Financial Markets (Stichting Autoriteit Financiële Markten) (the "**AFM**") on 6 April 2022 as competent authority under the Prospectus Regulation. The Prospectus has been notified to the Belgian Financial Services and Markets Authority for passporting in accordance with article 25 of the Prospectus Regulation. The Prospectus constitutes an EU recovery prospectus for the purposes of, and has been prepared in accordance with, Article 14a of the Prospectus Regulation (as amended by the Regulation (EU) 2021/337 of the European Parliament and of the Council of 16 February 2021) and in accordance with Commission Delegated Regulation No 2019/980/EU of 14 March 2019. The Prospectus is available electronically via the website of the Company <https://www.avantium.com/equityraise/> and the AFM website <https://www.afm.nl/nl-nl/professionals/registers/meldingenregisters/goedgekeurde-prospectussen>, subject to securities law restrictions in certain jurisdictions.

Previous announcements

On 9 December 2021, Avantium announced that it had taken a positive final investment decision on the construction of its FDCA Flagship Plant and that it was seeking shareholders' approval to raise €45 million in capital. On 25 January 2022 the Company announced that shareholders approved the construction of the world's first commercial FDCA Flagship Plant by granting the requested approvals at the Company's Extraordinary General Meeting, including the authorisation to the management board to issue €45 million in ordinary shares. On 23 March 2022, the Company announced its results for the financial year 2021. On 31 March 2022, Avantium announced that it had reached financial close for the FDCA Flagship Plant.

More information about this press release

Caroline van Reedt Dortland
Director Communications
+31 20 586 0110 / +31 6 1340 0179
mediarelations@avantium.com / ir@avantium.com

Information Line for Retail Investors

Retail investors with questions about the Offering can call the Avantium Information Line for retail investors (open from Monday to Friday during business hours) or send an email:
+31 (0) 10 313 8909
avantium@georgeson.com

About Avantium

Avantium is a leading technology development company and a forerunner in renewable chemistry. Avantium develops novel technologies based on renewable carbon sources as an alternative to fossil-based chemicals and plastics. The Company currently has three technologies at pilot and

demonstration phase. The most advanced technology is the YXY[®] plant-to-plastics-technology that catalytically converts plant-based sugars into FDCA (furanicarboxylic acid), the key building block for the sustainable plastic PEF (polyethylene furanoate). Avantium has successfully demonstrated the YXY[®] Technology at its pilot plant in Geleen, the Netherlands, and will commence construction of the world's first commercial plant for large-scale production of PEF in 2022 at its FDCA Flagship Plant in Delfzijl, the Netherlands. The second technology is Ray Technology[™] which catalytically converts industrial sugars to plantMEG[™] (mono-ethylene glycol) and plantMPG[™] (mono-propylene glycol). Avantium is scaling up its Ray Technology[™] and the demonstration plant in Delfzijl, the Netherlands opened in November 2019. The third technology is called the Dawn Technology[™] that converts non-food biomass into industrial sugars and lignin in order to transition the chemicals and materials industries to non-fossil resources. In 2018, Avantium opened the Dawn Technology[™] pilot biorefinery in Delfzijl, the Netherlands. In addition to developing and commercialising renewable chemistry technologies, the Company also provides advanced catalysis R&D services and systems to customers in the refinery and chemical industries. Avantium works in partnership with like-minded companies around the globe to create revolutionary renewable chemistry solutions from invention to commercial scale.

Avantium's shares are listed on Euronext Amsterdam and Euronext Brussels (symbol: AVTX). Its offices and headquarters are in Amsterdam, the Netherlands.

DISCLAIMER

These materials are not for release, distribution or publication, whether directly or indirectly and whether in whole or in part, in or into the United States Canada, Australia or Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

These materials are for information purposes only and are not intended to constitute, and should not be construed as, an offer to sell or a solicitation of any offer to buy the securities of the Company (such securities, the **Securities**) in the United States, Canada, Australia, the Republic of South Africa or Japan or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction.

This announcement is not for publication or distribution, directly or indirectly, in or into the United States. This announcement is not an offer of securities for sale into the United States. The Securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States. No public offering of securities is being made in the United States.

The Company has not authorised any offer to the public of Securities in any Member State of the European Economic Area other than the Netherlands. With respect to any Member State of the European Economic Area, other than the Netherlands (each a **Relevant Member State**), no action has been undertaken or will be undertaken to make an offer to the public of Securities requiring publication of a prospectus in any Relevant Member State. As a result, the Securities may only be offered in Relevant Member States (i) to any legal entity which is a qualified investor as defined in section 2(e) of the Prospectus Regulation; or (ii) in any other circumstances falling within section 1(4) of the Prospectus Regulation. For the purpose of this paragraph, the expression "offer of securities to the public" means the communication in any form and by any means of sufficient information on the terms of the offer and the Securities to be offered so as to enable the investor to decide to purchase or subscribe for the Securities and the expression "Prospectus Regulation" means Regulation (EU) 2017/1129 and includes any relevant delegated regulations.

In the United Kingdom, this announcement and any other materials in relation to the Securities is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" within the meaning of Article 2(e) of Prospectus Regulation as it forms part of English law by virtue of the European Union (Withdrawal) Act 2018 and who are (i) persons having professional experience

in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the **Order**); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it.

No action has been taken by the Company that would permit an offer of Securities or the possession or distribution of these materials or any other offering or publicity material relating to such Securities in any jurisdiction where action for that purpose is required.

The release, publication or distribution of these materials in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which they are released, published or distributed, should inform themselves about, and observe, such restrictions.

These materials may include statements, including the Company's financial and operational medium-term objectives that are, or may be deemed to be, "forward-looking statements". These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "plans", "projects", "anticipates", "expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Company's business, results of operations, financial position, liquidity, prospects, growth or strategies. Forward-looking statements speak only as of the date they are made.

Each of the Company and the Joint Bookrunners and their respective affiliates expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statement contained in these materials whether as a result of new information, future developments or otherwise

The Joint Bookrunners are acting exclusively for the Company and no one else in connection with any offering of Securities. They will not regard any other person as their respective clients in relation to any offering of Securities and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients nor for providing advice in relation to any offering of Securities, the contents of these materials or any transaction, arrangement or other matter referred to herein. None of the Joint Bookrunners or any of their respective subsidiary undertakings, affiliates or any of their respective directors, personally liable partners, officers, employees, advisers, agents, alliance partners or any other entity or person accepts any responsibility or liability whatsoever for, or makes any representation, warranty or undertaking, express or implied, as to the truth, accuracy, completeness or fairness of the information or opinions in these materials (or whether any information has been omitted from these materials) or any other information relating to the group, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of these materials or its contents or otherwise arising in connection therewith. Accordingly, the Joint Bookrunners disclaim, to the fullest extent permitted by applicable law, all and any liability, whether arising in tort or contract or that they might otherwise be found to have in respect of these materials and/or any such statement.

This announcement does not constitute a prospectus. An offer to acquire Securities pursuant to the proposed offering will be made, and any investor should make his investment, solely on the basis of information that will be contained in the Prospectus made generally available in the Netherlands in connection with such offering. Copies of the prospectus may be obtained through the website of the Company <https://www.avantium.com/equityraise/>.

This document contains information that qualifies as inside information within the meaning of section 7(1) of Regulation (EU) No 596/2014 on market abuse.

In connection with the Offering, each of the Joint Bookrunners and any of their affiliates, may take up a portion of the Securities in the Offering as a principal position and, in that capacity, may retain, purchase, sell, offer to sell for its own account such Securities and other securities of the Company or related investments in connection with the Offering or otherwise. In addition, each of the Joint Bookrunners and any of their affiliates may enter into financing arrangements (including swaps or contracts for differences) with investors in connection with which each of the Joint Bookrunners and any of their affiliates may from time to time acquire, hold or dispose of Securities. None of the Joint Bookrunners or their affiliates intends to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so.

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (MiFID II); (b) sections 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the MiFID II Product Governance Requirements), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Securities subject of the Offering have been subject to a product approval process, which has determined that such Securities are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the Target Market Assessment).

Notwithstanding the Target Market Assessment, "distributors" (for the purposes of the MiFID II Product Governance Requirements) should note that: the price of the Securities may decline and investors could lose all or part of their investment; the Securities offer no guaranteed income and no capital protection; and an investment in the Securities is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Offering.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Securities.

Each distributor is responsible for undertaking its own target market assessment in respect of the Securities and determining appropriate distribution channels.